CTRI/2015/02/005569进行中（未招募）1 期
Phase-I/II open label,safety and efficacy study of autologous adult stem cell therapy in end stage lung diseases-A pilot study
Global Hospiatls0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Ineffective clinical treatment,Limited physical activity,cessation of smoking for >6 months
排除标准
- •Patient on ventilator,Diagnosis of malignancy,H/o severe CAD,Significant liver kidney disease,psychiatric illness,Active smoker,Consent not given,Pregnancy,Diagnosed case of HIV,active TB,Secondary infections
研究者
相似试验
进行中（未招募）
1 期
Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03) - SECIMASMalignant AscitesMedDRA version: 12.0Level: PTClassification code 10025538Term: Malignant ascitesEUCTR2009-014076-22-BEFresenius Biotech GmbH30
进行中（未招募）
不适用
Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03) - SECIMASpatients with malignant ascites due to carcinomaMedDRA version: 12.1Level: LLTClassification code 10025538Term: Malignant ascitesEUCTR2009-014076-22-ITFRESENIUS BIOTECH GMBH30
进行中（未招募）
不适用
Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03). Estudio abierto de fase II para evaluar la seguridad de un segundo ciclo de infusión i.p. de catumaxomab en pacientes con ascitis maligna causada por un carcinoma que precisan la primera punción terapéutica tras el tratamiento del estudio CASIMAS (IP-CAT-AC-03). - SECIMASEUCTR2009-014076-22-ESFresenius Biotech GmbH30
进行中（未招募）
不适用
Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03) - SECIMASEUCTR2009-014076-22-SEFresenius Biotech GmbH30
进行中（未招募）
不适用
Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS study (IP-CAT-AC-03) - SECIMASMalignant AscitesMedDRA version: 12.0Level: PTClassification code 10025538Term: Malignant ascitesEUCTR2009-014076-22-FRFresenius Biotech GmbH30